相似文献
1
Apremilast.
Hosp Pharm. 2014 Sep;49(8):752-62. doi: 10.1310/hpj4908-752.
2
Umeclidinium bromide and vilanterol trifenatate inhalation powder.
Hosp Pharm. 2014 Jun;49(6):554-62. doi: 10.1310/hpj4906-554.
3
Tedizolid phosphate.
Hosp Pharm. 2014 Nov;49(10):961-71. doi: 10.1310/hpj4910-961.
4
Conjugated estrogens and bazedoxifene.
Hosp Pharm. 2014 Mar;49(3):273-83. doi: 10.1310/hpj4903-273.
5
Linaclotide.
Hosp Pharm. 2013 Feb;48(2):143-52. doi: 10.1310/hpj4802-143.
6
Dalbavancin.
Hosp Pharm. 2014 Oct;49(9):851-61. doi: 10.1310/hpj4909-851.
7
Alogliptin.
Hosp Pharm. 2013 Jul;48(7):580-92. doi: 10.1310/hpj4807-580.
8
Perampanel.
Hosp Pharm. 2013 Apr;48(4):321-31. doi: 10.1310/hpj4804-321.
9
Teriflunomide.
Hosp Pharm. 2013 Mar;48(3):231-40. doi: 10.1310/hpj4803-231.
10
Edoxaban.
Hosp Pharm. 2015 Jul;50(7):619-34. doi: 10.1310/hpj5007-619. Epub 2015 Jul 31.
引用本文的文献
1
[Phosphodiesterase 4 inhibitors in dermatology : Role in the treatment of skin diseases].
Dermatologie (Heidelb). 2024 Oct;75(10):791-797. doi: 10.1007/s00105-024-05407-7. Epub 2024 Aug 30.
2
Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules.
Front Pharmacol. 2022 Nov 24;13:1057083. doi: 10.3389/fphar.2022.1057083. eCollection 2022.
3
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
Molecules. 2022 Aug 4;27(15):4964. doi: 10.3390/molecules27154964.
4
Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice.
Biology (Basel). 2021 Dec 20;10(12):1355. doi: 10.3390/biology10121355.
5
Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.
Nat Rev Drug Discov. 2019 Oct;18(10):770-796. doi: 10.1038/s41573-019-0033-4. Epub 2019 Aug 6.
6
Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.
PLoS One. 2019 Apr 4;14(4):e0214857. doi: 10.1371/journal.pone.0214857. eCollection 2019.
7
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.
Front Pharmacol. 2018 Oct 17;9:1048. doi: 10.3389/fphar.2018.01048. eCollection 2018.
本文引用的文献
1
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Ann Rheum Dis. 2016 Jun;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963. Epub 2016 Jan 20.
2
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049.
3
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Ann Rheum Dis. 2014 Jun;73(6):1020-6. doi: 10.1136/annrheumdis-2013-205056. Epub 2014 Mar 4.
4
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e376-83. doi: 10.1111/j.1468-3083.2012.04716.x. Epub 2012 Oct 3.
5
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
Ann Rheum Dis. 2013 Sep 1;72(9):1475-80. doi: 10.1136/annrheumdis-2012-201915. Epub 2012 Sep 14.
6
Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
Arthritis Rheum. 2012 Oct;64(10):3156-67. doi: 10.1002/art.34627.
7
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Lancet. 2012 Aug 25;380(9843):738-46. doi: 10.1016/S0140-6736(12)60642-4. Epub 2012 Jun 29.
8
9
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Biochem Pharmacol. 2012 Jun 15;83(12):1583-90. doi: 10.1016/j.bcp.2012.01.001. Epub 2012 Jan 10.
10
Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
Xenobiotica. 2011 Dec;41(12):1063-75. doi: 10.3109/00498254.2011.604745. Epub 2011 Aug 23.
Zotero 插件